Archive for biopharmaceutical

Syntrix Wins U.S. Patent 9,000,142: Photocleavable Sense-Antisense Complex

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventor:  Zebala; John A. (Sammamish, WA) Abstract:  There is disclosed a photocleavable sense-antisense nucleobase polymer complex capable of modulating gene expression comprising an unnatural antisense nucleobase polymer that targets an mRNA, and a photocleavable sense nucleobase polymer noncovalently […]

Syntrix Wins U.S. Patent 8,993,541: Aminopyrimidine Carboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); Zebala, John A. (Sammamish, WA); and Schuler, Aaron D. (Auburn, WA).  Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, […]

Syntrix Wins U.S. Patent 8,981,106: Pyrimidinecarboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); and Zebala, John A. (Sammamish, WA).  Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there […]

Syntrix Featured in the NIH Innovation Zone at 2014 Bio International Convention in San Diego, CA

Syntrix was selected by the NIH to host a kiosk in the Innovation Zone, an area dedicated to showcasing Small Business Innovation Research (SBIR) grantees.  In addition, Syntrix was granted an additional opportunity to present their innovative research at the NIH Booth located in Hall A of the Discovery Zone.  The Syntrix presentation featured SX-682, […]

Syntrix Wins U.S. Patent 8,748,623: Pyridinecarboxamides as CXCR2 Modulators

Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean Y. (Seattle, WA); and Zebala, John A. (Sammamish, WA).  Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there […]

Syntrix Presents at the 2014 ACA Summit in Washington, D.C.

Syntrix was invited to present at the 2014 Angel Capital Association (ACA) Summit co-sponsored by the National Heart Lung and Blood Institute (NHLBI).  This conference brings together businesses, angel investors, and strategic partners from the biotech and pharmaceutical industries. It features presentations by top NHLBI-funded companies with innovative technologies.  The Syntrix presentation featured SX-682, the […]

Syntrix Presents at the 2009 NCI SBIR Investor Forum in Boston

Syntrix was one of 14 breakthrough technology companies invited to present at the 2009 SBIR Investor Forum sponsored by the National Cancer Institute (NCI). The chosen companies were selected from a highly competitive field of applicants by an independent panel of experts from venture capital firms, bio-pharmaceutical and medical device companies, based on their strength of research, impact on […]